Dry Eye Syndrome Treatment
Warsaw · Krakow · Vienna · Zurich
Dry Eye Syndrome (DES), also known as Dry Eye Disease (DED), is one of the most common problems diagnosed by ophthalmologists. This condition falls into the category of Ocular Surface Disease (OSD) and occurs in two main variants: that related to excessive tear film evaporation (Evaporative Dry Eye – EDE), accounting for approximately 80% of cases, and that caused by a deficiency of the aqueous component of the tear film (Aqueous-Deficient Dry Eye – ADDE), which accounts for the remaining 20% of cases.
Dry Eye Syndrome
In Poland, DES affects 10 to 18% of the population, and among contact lens wearers, this frequency can increase to 75%. The predisposition to this disorder increases with age and more often affects women. DES is characterized by complex etiology and symptoms, which may initially be mild but over time become so bothersome that they can lead to vision impairment.
Untreated DES can result in corneal epithelial erosion and even sterile ulcers, threatening vision loss. Chronic inflammation resulting from DES can lead to further damage to the ocular surface and worsening of symptoms.
Patients with Dry Eye Syndrome caused by excessive tear film evaporation often experience pain, discomfort, and burning and stinging in their eyes. They may also feel a gritty sensation under their eyelids, which can be very unpleasant, and notice temporary blurred vision or difficulty wearing contact lenses. In contrast, in individuals with DES where tear production is reduced, symptoms may include a foreign body sensation in the eye, conjunctival redness, eye fatigue, light sensitivity, and dryness of the mouth and mucous membranes. This is a symptom that should be monitored, as such dryness may also indicate Sjögren’s syndrome or other autoimmune connective tissue disorders.
Dry Eye Syndrome Treatment Methods – Method 1: E-EYE
Dry Eye Syndrome is a chronic and often burdensome condition that can significantly impact patients’ quality of life. Among the various treatment methods for this condition, both traditional therapies and modern technologies are used.
Traditional methods include the use of artificial tears and moisturizing ointments, which alleviate symptoms by supplementing the tear film. Anti-inflammatory drugs, such as cyclosporine A, which reduce inflammation on the ocular surface, are also often recommended.
At the SwissLaser clinic, we have the medical device E-EYE, which allows us to perform non-invasive, painless, and completely harmless procedures for the eyeball, helping to address Meibomian gland dysfunction. E-EYE generates multi-colored polychromatic pulsed light using the new IRPL® (Intense Regulated Pulsed Light) technology. As a result of the emission of so-called cold light, which safely activates the Meibomian glands, the production of polar lipids and non-polar fats is resumed, leading to the restoration of the proper structure of the tear film and the gradual disappearance of dry eye syndrome symptoms. Simply put: E-EYE stimulates the tear glands to increased activity.
Dry Eye Syndrome Treatment Methods – OptiLIGHT
However, the latest advancement in Dry Eye Syndrome treatment is the OptiLIGHT procedure, which reduces inflammation and improves tear film stability, significantly contributing to improved visual comfort for patients.
This technology effectively treats abnormal blood vessels that sustain inflammation and plays a key role in restoring proper Meibomian gland function. Additionally, due to its anti-inflammatory properties, OptiLIGHT reduces the population of Demodex mites, which can contribute to the exacerbation of DED symptoms.
How does OptiLIGHT technology differ from E-EYE technology?
OptiLIGHT technology and the E-EYE device are different systems used to treat similar problems.
OptiLIGHT
- Manufacturer: Lumenis
- Technology: Utilizes patented Optimal Pulse (OPT™) technology, which is a form of IPL (Intense Pulsed Light) therapy.
- Application: Focuses on treating Dry Eye Syndrome caused by Meibomian gland dysfunction, reducing inflammation, improving tear gland function, and stabilizing the tear film.
- Approval: It is the first and only FDA-approved IPL device for the treatment of Dry Eye Syndrome.
E-EYE Device
- Manufacturer: E-Swin
- Technology: Also uses IPL technology, but can be used in a slightly different way.
- Application: E-EYE is focused on stimulating the Meibomian glands, which improves their function and supports the production of lipids in the tear film, providing relief from DES symptoms.
- Specificity: E-EYE focuses on precise stimulation of specific areas around the eyes, providing highly effective therapy for patients with dry eye problems.
OptiLIGHT or E-EYE?
In summary, OptiLIGHT technology and the E-EYE device serve similar goals, namely treating problems associated with Dry Eye Syndrome. Both utilize pulsed light (IPL) technology, but may differ in details regarding design, functionality, and ultimate therapeutic effects.
Why undergo the OptiLIGHT procedure?
The OptiLIGHT procedure offers a range of benefits in the treatment of Dry Eye Syndrome caused by Meibomian gland dysfunction, making it an effective and modern therapeutic method.
Here are some of its advantages:
- Reduction of Demodex mite population. Helps reduce Demodex mites, which can contribute to eyelid margin inflammation.
- Effectiveness. High effectiveness in improving Dry Eye Syndrome symptoms after just a few sessions.
- Safety. It is a safe method, approved by the FDA as the first and only IPL therapy for DES.
- Non-invasiveness. The procedure is non-invasive, meaning minimal risk of complications and no recovery period required.
- Comfort. The procedure is painless, which increases patient comfort during therapy.
- Speed. Each session lasts only about 15 minutes, which is convenient for patients with limited time.
- Long-lasting effects. The effects of the procedure can last for a long time, from 7 months to even 2 years.
- Reduction of inflammation. OPT™ technology helps reduce inflammation on the ocular surface.
- Improvement of Meibomian gland function. The procedure restores proper Meibomian gland function, which is crucial for tear film stability.
- Treatment of vascular changes. Effectively reduces pathologically altered blood vessels that contribute to inflammation.
Contraindications for the OptiLIGHT procedure
OptiLIGHT therapy has several contraindications that should be considered before starting treatment:
- Migraine or epilepsy.
- Eye or eyelid surgery, or nerve paralysis within 6 months before the first IPL treatment.
- Unstable ocular disorders or diseases involving the ocular surface.
- Precancerous lesions, skin cancer, or pigmented lesions in the treated area.
- Unstable autoimmune diseases.
- Recent eye infections.
- History of herpes or rash around the mouth, including herpes simplex type 1 and 2, systemic lupus erythematosus, and porphyria.
- Use of photosensitizing drugs and/or herbal remedies that may cause photosensitivity within 3 months before the first IPL treatment.
- Recent or planned radiation therapy to the head or neck.
- Recent or planned chemotherapy.
Method 3: PRP Drops. What are they and how do they work on your eyes?
PRP drops (Platelet-Rich Plasma) are drops created from platelet-rich plasma, which is the liquid part of blood containing a high concentration of platelets. Platelets are rich in growth factors – natural substances that support regenerative processes in the body. PRP drops are therefore ideal for supporting eye tissue regeneration, moisturizing the eyes, and alleviating symptoms such as dryness or burning.
What’s more, PRP drops resemble regular tears, but they are better. Why? Because unlike artificial tears, which only moisturize the eye surface, PRP drops contain valuable components such as growth factors, cytokines, and anti-inflammatory proteins. These components not only moisturize but also support regenerative processes, helping to heal tissue damage and reduce inflammation. Thanks to the presence of growth factors, PRP drops can accelerate corneal epithelial regeneration, improve tissue structure, and restore the eye’s natural protective functions.
